Isomorphic Labs $5B Series C (www.cnbc.com)

🤖 AI Summary
Isomorphic Labs, the AI-driven drug discovery startup founded by former Google DeepMind CEO Demis Hassabis, has successfully secured $5 billion in a Series C funding round. This significant capital influx, co-led by prominent investors including Greenoaks, Sequoia Capital, and Andreessen Horowitz, comes just over three months after Hassabis transitioned from his leadership role at DeepMind. The funding will be pivotal in enhancing Isomorphic's mission to leverage AI for the design and development of innovative medicines. This landmark investment reflects the burgeoning interest and financial commitment within the AI/ML community towards transforming the drug discovery landscape. With a record $23.2 billion raised by drug discovery startups in 2026, Isomorphic is poised to expedite its foundational biology models and deepen its understanding of complex diseases. Hassabis emphasized that the goal is to translate AI advancements into clinical applications, particularly through the development of a proprietary drug design engine and a promising pipeline of therapeutic candidates. This initiative not only aims to expedite medication development but also holds the potential for meaningful patient impact, marking a significant leap in the intersection of AI and healthcare.
Loading comments...
loading comments...